Floxuridine-containing regime in the treatment of gestational trophoblastic tumor.
- Author:
Xi-run WAN
1
;
Xiu-yu YANG
;
Yang XIANG
;
Yu WU
;
Yan-mei YANG
;
Shu-jie YIN
;
Jie LI
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Antimetabolites, Antineoplastic; administration & dosage; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Choriocarcinoma; drug therapy; Dactinomycin; administration & dosage; Drug Administration Schedule; Female; Floxuridine; administration & dosage; Gestational Trophoblastic Disease; drug therapy; Humans; Hydatidiform Mole, Invasive; drug therapy; Middle Aged; Pregnancy; Uterine Neoplasms; drug therapy; Vincristine; administration & dosage
- From: Acta Academiae Medicinae Sinicae 2003;25(4):410-413
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyse the efficacy of the floxuridine (FUDR)-containing regime (single agent or in combination) in the treatment of gestational trophoblastic tumor.
METHODSSeventy-four patients with gestational trophoblastic tumors (GTT), 47 invasive mole and 27 choriocarcinoma, were treated with FUDR-containing regime. The clinical staging of the disease were: 33 cases of stage I, 3 cases of stage II, 31 cases of stage IIIa, 6 cases of stage IIIb, and 1 case of stage IV.
RESULTSThe cure rate of FUDR-containing regime in the treatment of GTT was 91.9% (68 out of 74 cases). Twenty-one out of these 74 patients showed drug resistant to 5-FU-containing or MTX-containing regime and were cured after they changed to the FUDR-containing regime. All 7 patients of advanced stage (> or = III b) got cured. The major adverse event of FUDR-containing regime was myelodepression and gastrointestinal toxicity: III-IV degree granulopenia 26%, III-IV thrombopenia 6.2%, III degree vomiting 57.1%, and III degree diarrhea 4.3%.
CONCLUSIONFUDR-containing regime is efficient for the treatment of GTT, even for those with advanced stage or drug-resistant disease.
